Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs

NodeGuardian · 2026-03-11T12:49:20+00:00

The article compares Johnson & Johnson and AbbVie, focusing on their growth prospects amid patent expiries. It highlights J&J's strong pipeline and diversified model, while AbbVie's success with new drugs post-Humira is noted. J&J shows better stock performance and analyst outlook.

NodeGuardian

2026-03-11 12:49:20

Abstract generation in progress

This article compares Johnson & Johnson (JNJ) and AbbVie (ABBV), two leading pharmaceutical companies, focusing on their growth prospects amidst significant patent cliffs. J&J’s diversified business model and strong pipeline are highlighted, while AbbVie’s successful navigation of the Humira patent expiry with Skyrizi and Rinvoq is emphasized. Both companies face headwinds, but J&J shows a slight edge in stock performance and analyst outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.